These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 20930090

  • 1. Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease.
    Meijer E, Bakker SJ, van der Jagt EJ, Navis G, de Jong PE, Struck J, Gansevoort RT.
    Clin J Am Soc Nephrol; 2011 Feb; 6(2):361-8. PubMed ID: 20930090
    [Abstract] [Full Text] [Related]

  • 2. Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment.
    Zittema D, Boertien WE, van Beek AP, Dullaart RP, Franssen CF, de Jong PE, Meijer E, Gansevoort RT.
    Clin J Am Soc Nephrol; 2012 Jun; 7(6):906-13. PubMed ID: 22516290
    [Abstract] [Full Text] [Related]

  • 3. Association of arginine vasopressin surrogate marker urinary copeptin with severity of autosomal dominant polycystic kidney disease (ADPKD).
    Nakajima A, Lu Y, Kawano H, Horie S, Muto S.
    Clin Exp Nephrol; 2015 Dec; 19(6):1199-205. PubMed ID: 25715868
    [Abstract] [Full Text] [Related]

  • 4. Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease.
    Boertien WE, Meijer E, Zittema D, van Dijk MA, Rabelink TJ, Breuning MH, Struck J, Bakker SJ, Peters DJ, de Jong PE, Gansevoort RT.
    Nephrol Dial Transplant; 2012 Nov; 27(11):4131-7. PubMed ID: 22523115
    [Abstract] [Full Text] [Related]

  • 5. Urine and plasma osmolality in patients with autosomal dominant polycystic kidney disease: reliable indicators of vasopressin activity and disease prognosis?
    Casteleijn NF, Zittema D, Bakker SJ, Boertien WE, Gaillard CA, Meijer E, Spithoven EM, Struck J, Gansevoort RT.
    Am J Nephrol; 2015 Nov; 41(3):248-56. PubMed ID: 25926129
    [Abstract] [Full Text] [Related]

  • 6. Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis.
    Meijer E, Boertien WE, Nauta FL, Bakker SJ, van Oeveren W, Rook M, van der Jagt EJ, van Goor H, Peters DJ, Navis G, de Jong PE, Gansevoort RT.
    Am J Kidney Dis; 2010 Nov; 56(5):883-95. PubMed ID: 20888104
    [Abstract] [Full Text] [Related]

  • 7. Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort.
    Boertien WE, Meijer E, Li J, Bost JE, Struck J, Flessner MF, Gansevoort RT, Torres VE, Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease CRISP.
    Am J Kidney Dis; 2013 Mar; 61(3):420-9. PubMed ID: 23089511
    [Abstract] [Full Text] [Related]

  • 8. Kidney function and plasma copeptin levels in healthy kidney donors and autosomal dominant polycystic kidney disease patients.
    Zittema D, van den Berg E, Meijer E, Boertien WE, Muller Kobold AC, Franssen CF, de Jong PE, Bakker SJ, Navis G, Gansevoort RT.
    Clin J Am Soc Nephrol; 2014 Sep 05; 9(9):1553-62. PubMed ID: 24993447
    [Abstract] [Full Text] [Related]

  • 9. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
    Boertien WE, Meijer E, de Jong PE, ter Horst GJ, Renken RJ, van der Jagt EJ, Kappert P, Ouyang J, Engels GE, van Oeveren W, Struck J, Czerwiec FS, Oberdhan D, Krasa HB, Gansevoort RT.
    Am J Kidney Dis; 2015 Jun 05; 65(6):833-41. PubMed ID: 25600953
    [Abstract] [Full Text] [Related]

  • 10. Effect of Vasopressin on the Hypothalamic-Pituitary-Adrenal Axis in ADPKD Patients during V2 Receptor Antagonism.
    Heida JE, Minović I, van Faassen M, Kema IP, Boertien WE, Bakker SJL, van Beek AP, Gansevoort RT.
    Am J Nephrol; 2020 Jun 05; 51(11):861-870. PubMed ID: 33147589
    [Abstract] [Full Text] [Related]

  • 11. Urinary EGF Receptor Ligand Excretion in Patients with Autosomal Dominant Polycystic Kidney Disease and Response to Tolvaptan.
    Harskamp LR, Gansevoort RT, Boertien WE, van Oeveren W, Engels GE, van Goor H, Meijer E.
    Clin J Am Soc Nephrol; 2015 Oct 07; 10(10):1749-56. PubMed ID: 26231191
    [Abstract] [Full Text] [Related]

  • 12. Apelin and copeptin: two opposite biomarkers associated with kidney function decline and cyst growth in autosomal dominant polycystic kidney disease.
    Lacquaniti A, Chirico V, Lupica R, Buemi A, Loddo S, Caccamo C, Salis P, Bertani T, Buemi M.
    Peptides; 2013 Nov 07; 49():1-8. PubMed ID: 23973863
    [Abstract] [Full Text] [Related]

  • 13. Copeptin levels and kidney function in ADPKD: case-control study.
    Corradi V, Martino F, Gastaldon F, Scalzotto E, Caprara C, Fortunato A, Pinaffo G, Marchetti C, Fabbi F, Giavarina D, Ferrari F, Rosner MH, Ronco C.
    Clin Nephrol; 2016 Sep 07; 86(9):147-53. PubMed ID: 27487355
    [Abstract] [Full Text] [Related]

  • 14. Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort.
    Meijer E, Bakker SJ, Halbesma N, de Jong PE, Struck J, Gansevoort RT.
    Kidney Int; 2010 Jan 07; 77(1):29-36. PubMed ID: 19847155
    [Abstract] [Full Text] [Related]

  • 15. Early renal abnormalities in autosomal dominant polycystic kidney disease.
    Meijer E, Rook M, Tent H, Navis G, van der Jagt EJ, de Jong PE, Gansevoort RT.
    Clin J Am Soc Nephrol; 2010 Jun 07; 5(6):1091-8. PubMed ID: 20413443
    [Abstract] [Full Text] [Related]

  • 16. Relationship of urinary endothelin-1 with estimated glomerular filtration rate in autosomal dominant polycystic kidney disease: a pilot cross-sectional analysis.
    Raina R, Lou L, Berger B, Vogt B, Do AS, Cunningham R, Vasavada P, Herrmann K, Dell K, Simonson M.
    BMC Nephrol; 2016 Feb 29; 17():22. PubMed ID: 26923419
    [Abstract] [Full Text] [Related]

  • 17. Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease.
    Gansevoort RT, van Gastel MDA, Chapman AB, Blais JD, Czerwiec FS, Higashihara E, Lee J, Ouyang J, Perrone RD, Stade K, Torres VE, Devuyst O, TEMPO 3:4 Investigators.
    Kidney Int; 2019 Jul 29; 96(1):159-169. PubMed ID: 30898339
    [Abstract] [Full Text] [Related]

  • 18. Urine Concentrating Capacity, Vasopressin and Copeptin in ADPKD and IgA Nephropathy Patients with Renal Impairment.
    Zittema D, Casteleijn NF, Bakker SJ, Boesten LS, Duit AA, Franssen CF, Gaillard CA, Gansevoort RT.
    PLoS One; 2017 Jul 29; 12(1):e0169263. PubMed ID: 28081165
    [Abstract] [Full Text] [Related]

  • 19. Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease.
    Messchendorp AL, Spithoven EM, Casteleijn NF, Dam WA, van den Born J, Tonnis WF, Gaillard CAJM, Meijer E, DIPAK Consortium.
    BMC Nephrol; 2018 Dec 19; 19(1):368. PubMed ID: 30567514
    [Abstract] [Full Text] [Related]

  • 20. Alterations of Proximal Tubular Secretion in Autosomal Dominant Polycystic Kidney Disease.
    Wang K, Zelnick LR, Chen Y, Hoofnagle AN, Watnick T, Seliger S, Kestenbaum B.
    Clin J Am Soc Nephrol; 2020 Jan 07; 15(1):80-88. PubMed ID: 31628117
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.